公开(公告)号：US20180127511A1

公开(公告)日：2018-05-10

申请号：US15784967

申请日：1918-10-16

Applicant: SANOFI

Inventor： Gillian PAYNE ,  Philip CHUN ,  Daniel J. TAVARES

IPC: C07K16/30 ,  A61K47/68 ,  A61K31/537 ,  C07K14/47 ,  C07K16/46

CPC classification number: C07K16/3092 ,  A61K31/537 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6859 ,  A61K47/6869 ,  A61K47/6877 ,  A61K2039/505 ,  C07K14/4727 ,  C07K14/4748 ,  C07K16/3015 ,  C07K16/303 ,  C07K16/3069 ,  C07K16/464 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/92

Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.

公开(公告)号：US20180100005A1

公开(公告)日：2018-04-12

申请号：US15789589

申请日：2017-10-20

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/08 ,  C07K16/30 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  C12N9/64 ,  G01N33/50 ,  G01N33/566 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  A61K38/06 ,  G01N33/569 ,  A61K38/17

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180078627A1

公开(公告)日：2018-03-22

申请号：US15563542

申请日：2016-03-28

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  TESSA THERAPEUTICS PTE. LTD.

Inventor： Jieming ZENG ,  Shu WANG ,  Andrew KHOO

IPC: A61K39/00 ,  C12N5/0784 ,  C12N7/00 ,  C07K14/47 ,  C07K14/435

CPC classification number: A61K39/0011 ,  A61K35/15 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/57 ,  A61K2039/572 ,  C07K14/435 ,  C07K14/4748 ,  C07K2319/95 ,  C12N5/0639 ,  C12N7/00 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N2502/1394 ,  C12N2506/02 ,  C12N2510/00 ,  C12N2740/15043

Abstract: There is provided a method of loading antigen in a dendritic cell for antigen presentation, the method comprising: modifying a pluripotent stem cell with a nucleic acid molecule encoding an antigen or one or more immunogenic epitopes thereof; inducing the pluripotent stem cell to differentiate into a dendritic cell that expresses and presents the antigen or the one or more immunogenic epitopes thereof. Dendritic cells, vaccines and methods of using the dendritic cells and vaccines are also provided.

公开(公告)号：US09910043B2

公开(公告)日：2018-03-06

申请号：US15046700

申请日：2016-02-18

Applicant: BioNTech AG

Inventor： Özlem Türeci ,  Ugur Sahin ,  Gerd Helftenbein ,  Volker Schlüter

IPC: G01N33/574 ,  C07K14/47 ,  C07K14/705 ,  C07K16/30 ,  C12Q1/68 ,  A61K39/00

CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/56

Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

公开(公告)号：US09909189B2

公开(公告)日：2018-03-06

申请号：US14943907

申请日：2015-11-17

Applicant: Gen-Probe Incorporated

Inventor： Ursula Busse ,  Camille Chypre ,  Yves Fradet

IPC: C07H21/04 ,  C12Q1/68 ,  C07K14/47 ,  G01N33/574 ,  C07K16/30

CPC classification number: C12Q1/6886 ,  A01K2217/05 ,  C07H21/04 ,  C07K14/47 ,  C07K14/4748 ,  C07K16/3069 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57434 ,  G01N2333/47 ,  G01N2800/56

Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.

公开(公告)号：US09907842B2

公开(公告)日：2018-03-06

申请号：US14819599

申请日：2015-08-06

Applicant: Ramila Philip

Inventor： Ramila Philip

IPC: A61K39/00 ,  C07K14/47 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61K39/00 ,  A61K2039/572 ,  C07K14/4748 ,  G01N33/57423

Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers.

公开(公告)号：US20180055883A1

公开(公告)日：2018-03-01

申请号：US15686679

申请日：2017-08-25

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WEIBE ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3053 ,  C12N5/0636 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180030109A1

公开(公告)日：2018-02-01

申请号：US15730441

申请日：2017-10-11

Applicant: Dirk Spitzer ,  William G Hawkins

Inventor： Dirk Spitzer ,  William G Hawkins

IPC: C07K14/705 ,  C12N15/63 ,  C07K14/47 ,  C12N15/62 ,  A61K38/17 ,  C12N15/74 ,  A61K38/19 ,  C12N15/70 ,  A61K38/00 ,  C12N15/79 ,  C07K14/525

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K38/17 ,  A61K38/1761 ,  A61K38/1764 ,  A61K38/177 ,  A61K38/191 ,  C07K14/4747 ,  C07K14/4748 ,  C07K14/525 ,  C07K14/70575 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/33 ,  C07K2319/43 ,  C07K2319/74 ,  C12N15/62 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12N15/79

Abstract: Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.

公开(公告)号：US20180009858A9

公开(公告)日：2018-01-11

申请号：US15229970

申请日：2016-08-05

Applicant: immatics biotechnology GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: C07K14/47 ,  C12N15/115 ,  A61K39/00 ,  G01N33/574 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/68 ,  C07K14/725 ,  A61K38/00

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N33/5748 ,  G01N33/6848 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180002391A1

公开(公告)日：2018-01-04

申请号：US15543877

申请日：2015-01-16

Applicant: MINOMIC INTERNATIONAL LTD.

Inventor： Douglas CAMPBELL ,  Irene JUSTINIANO FUENMAYOR ,  Aline NOCON ,  Julie SOON ,  Quach TRUONG ,  Bradley WALSH ,  Sandra WISSMUELLER

IPC: C07K14/47 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K14/4748 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/34 ,  C07K2317/565 ,  G01N33/57434

Abstract: The present invention relates to epitopes of glypican-1 (GPC-1) and uses thereof.